Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 13/20 | 0.55 |
| ▸ | F10 | P00742 | 2/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.50 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.50 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597808 | 0.92 | F2 (0.50) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL3278168 | 0.90 | F2 (0.60) | F2F10 | |
| SCHEMBL3279407 | 0.85 | F2 (0.54) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL3277603 | 0.79 | SMPD1 (0.48) | — | |
| SCHEMBL3281929 | 0.75 | F2 (0.58) | F2F10 | |
| SCHEMBL3284334 | 0.74 | MAOB (0.48) | — | |
| SCHEMBL3276910 | 0.73 | HDAC1 (0.46) | — | |
| SCHEMBL3277080 | 0.73 | RAB9A (0.45) | F2F10 | |
| SCHEMBL7448763 | 0.72 | F2 (0.85) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL4374899 | 0.71 | PLAAT3 (0.52) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700605-B2 | 2-cyano-pyrimidines and-triazines as cysteine protease inhibitors | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20080214548-A1 | 2-Cyano-Pyrimidines and-Triazines as Cysteine Protease Inhibitors | FLOHR STEFANIE | 2008-09-04 | — | — | US | disclosed |
| EP-1907368-A1 | 2-CYANO-PYRIMIDINES AND -TRIAZINES AS CYSTEINE PROTEASE INHIBITORS | Novartis AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009715-A1 | 2-CYANO-PYRIMIDINES AND -TRIAZINES AS CYSTEINE PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214548-A1 | 2-Cyano-Pyrimidines and-Triazines as Cysteine Protease Inhibitors | USP2, UCHL3, UCHL5 | F2 486/4885F10 2607/4885PRSS1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.